ArticlePsychopharmacology2026
Mood stabilizers and systemic inflammatory burden in euthymic patients with bipolar disorder: a comparative study of lithium and valproate.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleSystemic inflammation is increasingly recognized as a key component of the pathophysiology and neuroprogression of bipolar disorder (BD). Novel hematologic indices, including the NLR, PLR, SII, SIRI, and PIV, provide accessible measures of the inflammatory burden. However, the impact of mood stabilizers on these indices in patients with BD remains insufficiently explored.
objectiveTo investigate the association between mood stabilizer treatment (lithium and/or valproate [VPA]) and systemic inflammatory burden in euthymic patients with BD.
methodsThis study included 295 euthymic patients with BD who were followed up at a tertiary care center. Participants were categorized into four groups based on their current treatment: no lithium/VPA (n = 33), VPA (n = 102), lithium (n = 120), and lithium + VPA (n = 40). Sociodemographic and clinical variables, hematologic parameters, and derived inflammatory indices (NLR, PLR, SII, SIRI, and PIV) were compared between groups. Multiple linear regression analysis was performed to identify independent predictors of systemic inflammatory burden.
resultsAlthough most sociodemographic variables were comparable, patients receiving lithium + VPA exhibited a more severe illness course. The VPA group demonstrated significantly lower neutrophil counts and reduced NLR, PLR, SII, SIRI, and PIV values than the lithium and no lithium/VPA groups (all p<.001). In the regression analysis, VPA use independently associated lower SII levels (p=.021), whereas lithium use showed no significant association. Inflammatory indices were not correlated with the clinical course variables.
conclusionVPA use was associated with lower systemic inflammatory indices in euthymic patients with BD, whereas lithium use showed no significant association with reduced inflammatory burden. These findings should be interpreted as preliminary and hypothesis-generating, and future studies are needed to clarify the direction, mechanisms, and clinical significance of these associations.
Indexed as
Identifiers
42301417What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.